- $40.52m
- $22.11m
- $0.05m
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
U.S. STOCKS ON THE MOVE-Wendy's, Canadian Solar, Bio-Techne
U.S. STOCKS ON THE MOVE-Micron, Qualcomm, IBM
Brief: Inmune Bio Inc. Achieves Mhra Approval Of Pip For Cordstrom™
INmune Bio rises as UK backs plan for testing rare skin disease therapy in children
Brief: INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial
Brief: INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INmune Bio Q1 net loss narrows on lower R&D expenses
Brief: Inmune Bio And Anthony Nolan Announce Strategic Expansion
Brief: Inmune Bio Announces FDA Alignment On Integrated Phase 2B/3 Registration Pathway For Xpro1595 In Early Alzheimer’S Disease
Brief: Inmune Bio Announces FDA Alignment On Integrated Phase 2B/3 Registration Pathway For Xpro1595 In Early Alzheimer’S Disease
Brief: Inmune Bio Inc Submitted Pre-Submission Package For Cordstrom With Uk's Mhra
Brief: Inmune Bio Advances Cordstrom™ Towards Uk Marketing Authorization In Rdeb
INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO